Comparison of eight modern preoperative scoring systems for survival prediction in patients with extremity metastasis

Author:

Lee Tse‐Ying12,Chen Yu‐An2,Groot Olivier Q.34,Yen Hung‐Kuan56,Bindels Bas J. J.3,Pierik Robert‐Jan34ORCID,Hsieh Hsiang‐Chieh5,Karhade Aditya V.4,Tseng Ting‐En1,Lai Yi‐Hsiang2ORCID,Yang Jing‐Jen2,Lee Chia‐Che1,Hu Ming‐Hsiao1ORCID,Verlaan Jorrit‐Jan3,Schwab Joseph H.4,Yang Rong‐Sen1,Lin Wei‐Hsin1ORCID

Affiliation:

1. Department of Orthopaedic Surgery National Taiwan University Hospital Taipei Taiwan

2. Department of Medical Education National Taiwan University Hospital Taipei Taiwan

3. Department of Orthopaedic Surgery University Medical Center Utrecht–Utrecht University Utrecht Netherlands

4. Department of Orthopaedic Surgery Massachusetts General Hospital–Harvard Medical School Boston USA

5. Department of Orthopaedic Surgery National Taiwan University Hospital Hsin‐Chu Taiwan

6. Department of Medical Education National Taiwan University Hospital Hsin‐Chu Taiwan

Abstract

AbstractBackgroundSurvival is an important factor to consider when clinicians make treatment decisions for patients with skeletal metastasis. Several preoperative scoring systems (PSSs) have been developed to aid in survival prediction. Although we previously validated the Skeletal Oncology Research Group Machine‐learning Algorithm (SORG‐MLA) in Taiwanese patients of Han Chinese descent, the performance of other existing PSSs remains largely unknown outside their respective development cohorts. We aim to determine which PSS performs best in this unique population and provide a direct comparison between these models.MethodsWe retrospectively included 356 patients undergoing surgical treatment for extremity metastasis at a tertiary center in Taiwan to validate and compare eight PSSs. Discrimination (c‐index), decision curve (DCA), calibration (ratio of observed:expected survivors), and overall performance (Brier score) analyses were conducted to evaluate these models’ performance in our cohort.ResultsThe discriminatory ability of all PSSs declined in our Taiwanese cohort compared with their Western validations. SORG‐MLA is the only PSS that still demonstrated excellent discrimination (c‐indexes>0.8) in our patients. SORG‐MLA also brought the most net benefit across a wide range of risk probabilities on DCA with its 3‐month and 12‐month survival predictions.ConclusionsClinicians should consider potential ethnogeographic variations of a PSS's performance when applying it onto their specific patient populations. Further international validation studies are needed to ensure that existing PSSs are generalizable and can be integrated into the shared treatment decision‐making process. As cancer treatment keeps advancing, researchers developing a new prediction model or refining an existing one could potentially improve their algorithm's performance by using data gathered from more recent patients that are reflective of the current state of cancer care.

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3